Feb 23 (Reuters) – Online telehealth company Hims & Hers Health forecast 2026 revenue above estimates on Monday, betting on increased sales for its personalized healthcare offerings that include its compounded weight-loss drugs
However, shares of the company were down 2.5% in after-market trading after it forecast first-quarter revenue below estimates.
The stock is down 52% so far this year after its plan to launch a $49 compounded version of Novo Nordisk’s weight-loss pill Wegovy backfired due to swift backlash from U.S. authorities. Earlier this month, Hims said it planned to offer compounded copies of Novo’s new Wegovy pill at an introductory price of $49 per month.
The company then reversed course on its plans after the U.S. Food and Drug Administration said it would take action against manufacturers mixing ingredients to produce copies of GLP-1 drugs, referring it to the Department of Justice for potential violations of federal law.
It forecast revenue of $600 million to $625 million for the first quarter, missing estimates of $653.11 million, according to data compiled by LSEG.
Hims also expects 2026 revenue to be in the range of $2.7 billion to $2.9 billion, compared to estimates of $2.74 billion.
The company said its outlook gives “flexibility to lean into future investments” and said will keep it on track for its 2030 target of more than $6.5 billion in revenue.
Hims and rivals have launched programs that offer “personalized” versions of semaglutide, the active ingredient in Novo Nordisk’s weight-loss drug Wegovy, at doses not accessible through the branded manufacturers, following the government’s ban on the mass production of copies.
The company’s subscriber base increased to 2.5 million, up 13% from the prior year.
It reported quarterly revenue of $617.8 million, an increase of 28% year-over-year, but below the analysts’ average estimate of $619.22 million.
(Reporting by Sneha S K in Bengaluru; Editing by Alan Barona)
Comments